Novo Acquires Three Kallyope Obesity Programs
Novo Nordisk acquired three early-stage non-incretin obesity programs from Kallyope, including IND-ready peptide K-554, a follow-on small molecule against an undisclosed novel target, and a separate small-molecule receptor agonist. Financial terms and specific targets…
